Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
Sunday, October 25, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Summit Therapeutics' partner Akeso reported positive results from the Phase III HARMONi-GI1 study. The study compared ivonescimab plus chemotherapy to durvalumab plus chemotherapy for advanced biliary tract cancer. Ivonescimab demonstrated overall survival superiority, marking a significant advancement in treatment options. The findings were presented at the European Society for Medical Oncology.
Market Sentiment Analysis
POSITIVE FACTORS
Ivonescimab shows overall survival superiority.
Positive results from Phase III HARMONi-GI1 study.
Potential first-in-class bispecific antibody.
Study presented at a major European symposium.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
32%
average across 5 past catalysts
Cash runway
~12 mo
Medium dilution risk
Lead asset
Ivonescimab
NDA/BLA · Non-Squamous Non-small Cell Lung Cancer
Full Press Release Details
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). These data are featured in today’s Presidential Symposium II at the European Society for Medic
Frequently Asked Questions
What is ivonescimab?
Ivonescimab is a novel bispecific antibody being evaluated for cancer treatment.
What was the outcome of the HARMONi-GI1 study?
The study showed that ivonescimab plus chemotherapy had superior overall survival.
Where were the study results presented?
The results were presented at the European Society for Medical Oncology symposium.